spironolactone has been researched along with Arrhythmias, Cardiac in 53 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of the investigation was the study of influence of spironolactone (25-75 mg/day) on clinico-functional and neurohormonal, 24-hour variability of cardiac rhythm, and ventricular disturbances of heart rhythm in patients with chronic heart failure (CHF) receiving optimal therapy." | 9.13 | [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy]. ( Baklanova, NA; Belenkov, IuN; Chelmakina, SM; Mareev, VIu; Orlova, IaA; Skvortsov, AA, 2008) |
| "Our results suggest that reducing cellular magnesium efflux and loss may contribute to the spironolactone-reduced arrhythmias in patients with CHF." | 9.12 | Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. ( Adhikari, CM; Gao, X; Lin, J; Peng, L; Zuo, Z, 2007) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 7.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 7.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 7.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| "Triamterene therapy was evaluated in 35 patients with congestive heart failure over a period of two and one-half years." | 7.64 | CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE. ( LAUFER, ST; MAHABIR, RN, 1964) |
| "Ventricular arrhythmia was recognized as the most common cause of death in this population." | 6.69 | Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. ( Coelho, O; Gruppi, CJ; Mady, C; Mansur, A; Maranhão, M; Ramires, FJ; Ramires, JA, 2000) |
| "Ventricular arrhythmias detected on 24 hour Holter monitoring didn't differ between the study groups." | 6.69 | [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure]. ( Bednarz, B; Chamiec, T; Cybulski, J, 2000) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 6.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Prompt recognition of the arrhythmia and immediate restoration of the cardiac rate and rhythm by pacemaker support followed by intensive regimen to lower the serum potassium prevented a potentially fatal outcome." | 5.26 | Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia. ( Patel, A; Thomsen, J; Yap, V, 1976) |
| "Aim of the investigation was the study of influence of spironolactone (25-75 mg/day) on clinico-functional and neurohormonal, 24-hour variability of cardiac rhythm, and ventricular disturbances of heart rhythm in patients with chronic heart failure (CHF) receiving optimal therapy." | 5.13 | [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy]. ( Baklanova, NA; Belenkov, IuN; Chelmakina, SM; Mareev, VIu; Orlova, IaA; Skvortsov, AA, 2008) |
| "Our results suggest that reducing cellular magnesium efflux and loss may contribute to the spironolactone-reduced arrhythmias in patients with CHF." | 5.12 | Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. ( Adhikari, CM; Gao, X; Lin, J; Peng, L; Zuo, Z, 2007) |
| "Randomized controlled trials demonstrate the efficacy of aldosterone receptor antagonists (spironolactone and eplerenone) as a useful pharmacologic intervention specifically in patients with New York Heart Association (NYHA) class III and IV heart failure, in patients with an ejection fraction <40% after myocardial infarction, and most recently in patients with mildly symptomatic heart failure." | 4.88 | Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. ( Coplan, NL; Markowitz, M; Messineo, F, 2012) |
| "Dogs subjected to RVP for 8 weeks in the absence or presence of eplerenone treatment during the final 4 weeks of pacing were assessed by echocardiography, electrophysiology study,ventricular fibrosis measurements, and inflammatory cytokine mRNA expression analysis." | 3.80 | Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure. ( , 2014) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 3.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 3.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| "Triamterene therapy was evaluated in 35 patients with congestive heart failure over a period of two and one-half years." | 3.64 | CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE. ( LAUFER, ST; MAHABIR, RN, 1964) |
| "Aldosterone blockade has been shown to reduce the incidence of sudden death in patients with heart failure." | 2.73 | Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. ( Donnan, PT; Pringle, SD; Shah, NC; Struthers, AD, 2007) |
| "Ventricular arrhythmia was recognized as the most common cause of death in this population." | 2.69 | Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. ( Coelho, O; Gruppi, CJ; Mady, C; Mansur, A; Maranhão, M; Ramires, FJ; Ramires, JA, 2000) |
| "Ventricular arrhythmias detected on 24 hour Holter monitoring didn't differ between the study groups." | 2.69 | [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure]. ( Bednarz, B; Chamiec, T; Cybulski, J, 2000) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 2.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Emphasis is on the arrhythmia component and the complex interrelationships of critical electrolytes and pathophysiologic factors that can lead to sudden cardiac death." | 1.28 | Short- and long-term mechanisms of sudden cardiac death in congestive heart failure. ( Helfant, RH, 1990) |
| "Additional evidence suggests that sudden death may occasionally result from this VEA." | 1.27 | Potassium loss, ventricular irritability, and the risk of sudden death in hypertensive patients. ( Holland, OB, 1986) |
| "Total starvation is effective for acute weight reduction in obesity." | 1.26 | [Complications in null-diet]. ( Mordasini, R; Oster, P; Raetzer, H; Schellenberg, B; Schlierf, G, 1977) |
| "Prompt recognition of the arrhythmia and immediate restoration of the cardiac rate and rhythm by pacemaker support followed by intensive regimen to lower the serum potassium prevented a potentially fatal outcome." | 1.26 | Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia. ( Patel, A; Thomsen, J; Yap, V, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (45.28) | 18.7374 |
| 1990's | 2 (3.77) | 18.2507 |
| 2000's | 16 (30.19) | 29.6817 |
| 2010's | 7 (13.21) | 24.3611 |
| 2020's | 4 (7.55) | 2.80 |
| Authors | Studies |
|---|---|
| Mc Causland, FR | 1 |
| Hsu, JY | 1 |
| Himmelfarb, J | 1 |
| Ikizler, TA | 1 |
| Raj, DS | 1 |
| Mehrotra, R | 1 |
| Waikar, SS | 1 |
| Kimmel, PL | 1 |
| Kliger, AS | 1 |
| Dember, LM | 1 |
| Charytan, DM | 1 |
| Pun, PH | 1 |
| García-Beltran, C | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Malpique, R | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Villarroya, F | 1 |
| Huang, Y | 1 |
| Liu, H | 1 |
| Wu, C | 1 |
| Fang, L | 1 |
| Fang, Q | 1 |
| Wang, Q | 1 |
| Fei, Y | 1 |
| Guo, X | 1 |
| Zhang, S | 1 |
| Esposito, CT | 1 |
| Varahan, S | 1 |
| Jeyaraj, D | 1 |
| Lu, Y | 1 |
| Stambler, BS | 1 |
| Petramala, L | 1 |
| Savoriti, C | 1 |
| Zinnamosca, L | 1 |
| Marinelli, C | 1 |
| Settevendemmie, A | 1 |
| Calvieri, C | 1 |
| Catani, M | 1 |
| Letizia, C | 1 |
| Yu, HD | 1 |
| Xia, S | 1 |
| Zha, CQ | 1 |
| Deng, SB | 1 |
| Du, JL | 1 |
| She, Q | 1 |
| Joseph, J | 1 |
| Claggett, BC | 1 |
| Anand, IS | 1 |
| Fleg, JL | 1 |
| Huynh, T | 1 |
| Desai, AS | 1 |
| Solomon, SD | 1 |
| O'Meara, E | 1 |
| Mckinlay, S | 1 |
| Pitt, B | 1 |
| Pfeffer, MA | 1 |
| Lewis, EF | 1 |
| Berger, R | 1 |
| Shankar, A | 1 |
| Fruhwald, F | 1 |
| Fahrleitner-Pammer, A | 1 |
| Freemantle, N | 1 |
| Tavazzi, L | 1 |
| Cleland, JG | 1 |
| Pacher, R | 1 |
| Jansen, PM | 1 |
| Danser, AH | 1 |
| Imholz, BP | 1 |
| van den Meiracker, AH | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Markowitz, M | 1 |
| Messineo, F | 1 |
| Coplan, NL | 1 |
| LAUFER, ST | 1 |
| MAHABIR, RN | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Csanády, M | 1 |
| Ostrenga, A | 1 |
| Pitcock, J | 1 |
| Pitcock, M | 1 |
| Micheletta, F | 1 |
| Natoli, S | 1 |
| Iuliano, L | 1 |
| Gao, X | 1 |
| Peng, L | 1 |
| Adhikari, CM | 1 |
| Lin, J | 1 |
| Zuo, Z | 1 |
| Krakoff, LR | 1 |
| Shah, NC | 1 |
| Pringle, SD | 1 |
| Donnan, PT | 1 |
| Struthers, AD | 2 |
| Skvortsov, AA | 1 |
| Mareev, VIu | 1 |
| Orlova, IaA | 1 |
| Chelmakina, SM | 1 |
| Baklanova, NA | 1 |
| Belenkov, IuN | 1 |
| Daum, S | 1 |
| Goerg, R | 1 |
| Schlehe, H | 1 |
| Wang, D | 1 |
| Koate, P | 1 |
| Diouf, S | 1 |
| Sylla, M | 1 |
| Diop, G | 1 |
| Diop, SN | 1 |
| Ramires, FJ | 1 |
| Mansur, A | 1 |
| Coelho, O | 1 |
| Maranhão, M | 1 |
| Gruppi, CJ | 1 |
| Mady, C | 1 |
| Ramires, JA | 1 |
| Bednarz, B | 1 |
| Cybulski, J | 1 |
| Chamiec, T | 1 |
| Beck, L | 1 |
| Blanc-Guillemaud, V | 1 |
| Cherif, OK | 1 |
| Jover, B | 1 |
| Davy, JM | 1 |
| Gronda, E | 1 |
| Mangiavacchi, M | 1 |
| Andreuzzi, B | 1 |
| Municinò, A | 1 |
| Berlin, D | 1 |
| Musgrave, GE | 1 |
| Born, CK | 1 |
| Davidson, CP | 1 |
| Hamrick, ME | 1 |
| Lawson, DH | 1 |
| Hutcheon, AW | 1 |
| Jick, H | 1 |
| Osswald, H | 1 |
| Ohmae, M | 1 |
| Nohara, Y | 1 |
| Takayasu, M | 1 |
| Saimyoji, H | 1 |
| Seriu, Y | 1 |
| Oster, P | 1 |
| Mordasini, R | 1 |
| Raetzer, H | 1 |
| Schellenberg, B | 1 |
| Schlierf, G | 1 |
| Follath, F | 1 |
| Roth, M | 1 |
| Wenk, M | 1 |
| Peyer, H | 1 |
| Fridrich, R | 1 |
| Slany, J | 1 |
| Mösslacher, H | 1 |
| Yap, V | 1 |
| Patel, A | 1 |
| Thomsen, J | 1 |
| Helfant, RH | 1 |
| Holland, OB | 1 |
| Stewart, DE | 1 |
| Ikram, H | 1 |
| Espiner, EA | 1 |
| Nicholls, MG | 1 |
| Thind, GS | 1 |
| Blakemore, WS | 1 |
| Zinsser, HF | 1 |
| Raynaud, R | 1 |
| Brochier, M | 1 |
| Raynaud, P | 1 |
| Fauchier, JP | 1 |
| Lvoff, R | 1 |
| Wilcken, DE | 1 |
| Fleming, JS | 1 |
| Leemhuis, MP | 1 |
| Struyvenberg, A | 1 |
| Krámer, KD | 1 |
| Vogt, W | 1 |
| Ghabussi, P | 1 |
| Hochrein, H | 1 |
| Pongpaew, C | 1 |
| Songkhla, RN | 1 |
| Kozam, RL | 1 |
| Salvador, M | 1 |
| Thomas, C | 1 |
| Mazenq, M | 1 |
| Conté, J | 1 |
| Mériel, P | 1 |
| Lesbre, P | 1 |
| Gardere, J | 1 |
| Smolenskiĭ, VS | 2 |
| Kun, IS | 1 |
| Khodzhamirova, VS | 1 |
| Gel'fond, MB | 2 |
| Topchiashvili, IuS | 1 |
| Khodzhamirov, VS | 1 |
| Samosiuk, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
6 reviews available for spironolactone and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Aldosterone-receptor antagonism in hypertension.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; D | 2009 |
Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.
Topics: Arrhythmias, Cardiac; Coronary Artery Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid R | 2012 |
A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure.
Topics: Arrhythmias, Cardiac; Drug Interactions; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; | 2005 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; A | 2001 |
Significance of hypokalaemia due to diuretics.
Topics: Amiloride; Arrhythmias, Cardiac; Chlorothiazide; Diuretics; Ethacrynic Acid; Extracellular Space; Fu | 1973 |
9 trials available for spironolactone and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial.
Topics: Arrhythmias, Cardiac; Humans; Mineralocorticoid Receptor Antagonists; Renal Dialysis; Spironolactone | 2023 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; B | 2009 |
Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Erythrocytes; Exercise | 2007 |
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
Topics: Aged; Aldosterone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over Studies; Double-Blind Me | 2007 |
[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rat | 2008 |
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Topics: Analysis of Variance; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, | 2000 |
[Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure].
Topics: Aged; Arrhythmias, Cardiac; Diuretics; Electrocardiography, Ambulatory; Female; Furosemide; Heart Fa | 2000 |
[Influence of spirolactone on the myocardial potassium balance following strophanthin in man (author's transl)].
Topics: Arrhythmias, Cardiac; Blood Pressure; Cardiac Glycosides; Heart; Hemodynamics; Humans; Myocardium; P | 1976 |
38 other studies available for spironolactone and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Spironolactone and Cardiac Arrhythmias in Hemodialysis Patients: Helpful or Harmful?
Topics: Arrhythmias, Cardiac; Humans; Mineralocorticoid Receptor Antagonists; Renal Dialysis; Spironolactone | 2023 |
Ventricular arrhythmia predicts poor outcome in polymyositis/dermatomyositis with myocardial involvement.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2021 |
Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiological Phenomena; Fibrosis; Heart Failure; Heart | 2013 |
Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Arrhythmias, Cardiac; Electr | 2013 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 2014 |
Spironolactone Regulates HCN Protein Expression Through Micro-RNA-1 in Rats With Myocardial Infarction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Gene Expression Regulation; Hyperpolarization | 2015 |
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiovascular Diseases; Cohort Studies; Electrocardi | 2016 |
High potassium. Too much of a good thing.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents | 2009 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
CLINICAL EXPERIENCE WITH A NEW DIURETIC, TRIAMTERENE, IN CONJESTIVE HEART FAILURE.
Topics: Arrhythmias, Cardiac; Canada; Chlorides; Digitalis Glycosides; Diuretics; Edema; Heart Failure; Hydr | 1964 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperka | 2004 |
More on the history of arrhythmia in long QT syndrome.
Topics: Arrhythmias, Cardiac; Cation Transport Proteins; Diuretics; DNA-Binding Proteins; ERG1 Potassium Cha | 2004 |
Implantable cardioverter-defibrillator therapy after myocardial infarction.
Topics: Arrhythmias, Cardiac; Defibrillators, Implantable; Eplerenone; Humans; Mineralocorticoid Receptor An | 2005 |
Is aldosterone a pro-arrhythmic hormone?
Topics: Aldosterone; Arrhythmias, Cardiac; Coronary Artery Disease; Humans; Peptide Fragments; Procollagen; | 2007 |
[Long-term domiciliary oxygen therapy of cardiac failure and cardiac arrhythmia accompanying respiratory insufficiency (author's transl)].
Topics: Adult; Aged; Arrhythmias, Cardiac; Digitalis; Heart Failure; Humans; Long-Term Care; Male; Middle Ag | 1981 |
[Value of successive use of aldactone and aldactacine in the management of congestive heart failure involving at the outset hypokalemia with or without cardiac rhythm disorders].
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Hypokalemia; Ma | 1981 |
Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Chronic Disease; Disease Mo | 2001 |
Sudden death due to cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Death, Sudden, Cardiac; Diuretics; Humans; Spironolactone | 2002 |
Interaction of spironolactone and digoxin in dogs.
Topics: Adenosine Triphosphatases; Animals; Arrhythmias, Cardiac; Biological Availability; Blood Pressure; D | 1977 |
Life threatening drug reactions amongst medical in-patients.
Topics: Aged; Arrhythmias, Cardiac; Bethanidine; Digoxin; Drug-Related Side Effects and Adverse Reactions; F | 1979 |
[Aldosterone antagonists in coronary insufficiency].
Topics: Arrhythmias, Cardiac; Canrenoic Acid; Heart Failure; Humans; Myocardial Contraction; Myocardial Infa | 1978 |
Paroxysmal atrial fibrillation with asystole and syncope: report of a case of sinus node dysfunction with hypokalemia and hypertension.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Heart Arrest; Humans; Hypertension; Hypokalemia; Male; Mi | 1976 |
[Complications in null-diet].
Topics: Acetone; Adult; Allopurinol; Arrhythmias, Cardiac; Diet, Reducing; Edema; Female; Humans; Ischemic A | 1977 |
[Determination of serum digoxin: a path to better control of therapy?].
Topics: Arrhythmias, Cardiac; Digitalis Glycosides; Digoxin; Drug Interactions; Humans; Spironolactone | 1977 |
Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia.
Topics: Aged; Arrhythmias, Cardiac; Humans; Hyperkalemia; Male; Potassium; Salts; Spironolactone; Uremia | 1976 |
Short- and long-term mechanisms of sudden cardiac death in congestive heart failure.
Topics: Aldosterone; Arrhythmias, Cardiac; Death, Sudden; Diuretics; Heart Failure; Humans; Magnesium; Potas | 1990 |
Potassium loss, ventricular irritability, and the risk of sudden death in hypertensive patients.
Topics: Amiloride; Arrhythmias, Cardiac; Death, Sudden; Diuretics; Humans; Hypertension; Hypokalemia; Magnes | 1986 |
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease.
Topics: Amiloride; Arrhythmias, Cardiac; Chlorthalidone; Coronary Disease; Cyclopenthiazide; Diuretics; Fema | 1985 |
Direct current cardioversion in digitalized patients with mitral valve disease.
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardiac Complexes, Pr | 1969 |
[Hyperkalemias in cardiac patients].
Topics: Acidosis; Acute Kidney Injury; Adult; Aged; Arrhythmias, Cardiac; Digitalis Glycosides; Diuretics; F | 1974 |
Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Digital | 1972 |
Heart failure and cardiac arrhythmias.
Topics: Arrhythmia, Sinus; Arrhythmias, Cardiac; Coronary Disease; Digoxin; Diuretics; Electroconvulsive The | 1974 |
[Therapeutic value of the aldosterone antagonist potassium canrenoate in digitalis intoxication (clinical studies at an internal intensive ward)].
Topics: Aged; Arrhythmias, Cardiac; Digitalis Glycosides; Female; Humans; Male; Middle Aged; Spironolactone | 1973 |
Hyperkalemic cardiac arrhythmia secondary to spironolactone.
Topics: Aged; Arrhythmias, Cardiac; Bicarbonates; Electrocardiography; Heart Failure; Heart Rate; Humans; Hy | 1973 |
[Rhythm disorders induced directly or by potassium depletion. General review apropos of 20 cases].
Topics: Aged; Alcoholic Intoxication; Arrhythmias, Cardiac; Cathartics; Cell Membrane; Cell Membrane Permeab | 1970 |
[Hypokalemias and their myocardial disorders].
Topics: Arrhythmias, Cardiac; Diagnosis, Differential; Digitalis Glycosides; Electrocardiography; Heart; Hum | 1971 |
[Elimination of digitalis-induced arrhythmia with concurrent antagonists of aldosterone and cocarboxylase].
Topics: Adult; Aged; Arrhythmias, Cardiac; Digitalis Glycosides; Female; Humans; Male; Middle Aged; Mineralo | 1969 |
[Clinical use of concurrent antagonists of aldosterone in patients with cardiac insufficiency].
Topics: Adult; Arrhythmias, Cardiac; Caproates; Cardiac Glycosides; Diuretics; Drug Tolerance; Ethisterone; | 1969 |